PubMed چکیده/رکورد

Continuous glucose monitoring for prediabetes classification in a large real-world cohort: Comparison with HbA1c and fasting plasma glucose.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

AIMS: Prediabetes classification based on hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) shows substantial discordance, potentially limiting early identification of individuals at metabolic risk. We evaluated whether continuous glucose monitoring (CGM) metrics can classify prediabetes with performance approaching that of HbA1c and FPG. METHODS: We conducted a cross-sectional analysis of 1,883 participants from the Human Phenotype Project with concurrent CGM, HbA1c, and FPG data. Individual CGM metrics were evaluated across four ADA-based laboratory reference definitions, and a combined model incorporating six clinically selected CGM metrics was additionally assessed. Discrimination was quantified using the area under the receiver operating characteristic curve (AUC). RESULTS: HbA1c- and FPG-based classifications showed marked discordance, with only 9.5% of participants meeting both prediabetes criteria. Several CGM metrics demonstrated classification performance approaching that of laboratory markers (AUC range 0.645-0.677). Discrimination improved when prediabetes was defined by both criteria, but no single marker achieved high performance independently. CONCLUSIONS: CGM metrics achieve classification performance approaching conventional laboratory markers while capturing complementary aspects of glycemic regulation. These findings support CGM as a complementary rather than standalone tool alongside conventional markers, particularly when laboratory results are discordant. Prospective studies incorporating oral glucose tolerance testing and longitudinal outcomes are warranted.

متن کامل اصلی

متن در JumpToDate ذخیره نشده است.

برای بررسی دسترسی کتابخانه‌ای یا خرید، رکورد اصلی را باز کنید.

رفتن به منبع اصلی

کلیدواژه‌ها

ClassificationContinuous glucose monitoringFasting plasma glucoseHbA1cPrediabetes
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Pharmacological strategies for slowing the rise of creatinine and urea nitrogen in diabetic kidney disease: A scoping review.

BACKGROUND: Adolescent diabetic kidney disease (DKD) represents an early-onset microvascular complication characterized by prolonged metabolic exposure and accelerated renal decline. Elevated serum creatinine and blood urea nitrogen (BUN) are key biochemical indicators of impaired renal function. OBJECTIVES: This scoping review aims to systematically map and evaluate pharmacological strategies for slowing the rise of creatinine and BUN…

PubMed2026

Dried Blood Spots for Doping Purpose-Two-Step Protocol for Analysis of Non-Threshold Substances and Anabolic Steroid Esters From One Spot/Pebble.

Analytical performance in anti-doping science continues to evolve through the identification of novel metabolites, improved detection sensitivity, and the use of alternative biological matrices. In recent years, dried blood spots (DBS) have gained increasing attention in doping control due to advantages such as improved analyte stability and simplified, cost-effective sample collection, shipment, and storage. However, DBS sampling is i…

PubMed2026

Hematology and Serum Biochemistry Reference Intervals for Captive-Born Owl Monkeys (Aotus nancymae): Effects of Age and Sex.

BACKGROUND: Owl monkeys (Aotus spp.) are a nocturnal nonhuman primate (NHP) native to central and South America that are used as infectious disease research models for human diseases, such as malaria and human immunodeficiency virus. Natural and infectious diseases may cause alterations in the hematology and serum biochemistry values, which necessitate the availability of reliable reference intervals for healthy animals. METHODS: In th…

PubMed2026

Quantitation of Tucatinib, a Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC-ESI-MS/MS: Application to a Pharmacokinetic Study in Mice.

Tucatinib (Irbinitinib, ARRY-380), a potent oral, selective HER2 kinase inhibitor that the FDA, has approved for the treatment of HER2-positive metastatic breast cancer and colorectal cancer. Tucatinib provides a powerful, targeted therapy for HER2-positive cancers, showing substantial benefits in survival and disease control, especially for patients with difficult-to-treat brain metastases, extending options beyond standard chemothera…